Genomics Blog

July 10, 2015 9:47 AM
LISTEN: Wylie Burke on genomics, precision medicine, and healthcare policy
Genomics is not simple. And no, we're not suggesting that is just a problem for Barbie. Understanding the science, the clinical application, and the societal implication of the new science of genomics is indeed hard. Human genetics is a key part of the hope and promise of personalized medicine but it remains a work in progress that has not lived up to the expectations society has pinned to the science.
Genome Alberta has funded a special project that focuses on how personalized (or precision) medicine can or should be incorporated into the health care system.
July 3, 2015 10:55 AM
Speeding up clinical development with better data
BIO2015 podcast with Mats Olsen from Prevail InfoworksThere is no question that in the 21st century data rules in the field of medicine, healthcare, and research. Apart from mistakes and dead-end roads when the data is wrong, companies and researchers need data quickly to get funding, to get drugs approvals, and to get regulatory or financial paperwork done efficiently. Managing that process is a specialty and there are many 3rd party tools and companies with the sole purpose of data management and integration.
It may not have the flair of working in the lab but just try and get things done without it. Mats Olsen knows all about getting the job done. He is SVP, Business Operations with Prevail Infoworks in Philadelphia where BIO 2015 was held in late June. His company made the most of having so many current and potential customers right in their backyard and I caught up with him for a few minutes to learn more about the importance of getting the data right. Here's our conversation.
July 3, 2015 8:48 AM
A Mo-POD for field medicine
Interview with Julie Bick from FlowMetricsIn my time spent as a journalist I spent time digging for stories but was always surprised and pleased to have stories drop in unexpectedly. The same thing happens every year at BIO when I'm doing our BIORadio podcasts and this is one of those stories. Someone overheard me doing one of the live streamed interviews and after I was free suggested I find out about a field diagnostics device that could be used in remote locations or in emergency situations. It turned out to be  an interesting story that even had a Canadian connection.
Here's my interview with Julie Bick, the Chief Scientific Officer with FlowMetric Diagnostics
June 23, 2015 2:11 PM
Hacking Medicine at BIO 2015
If you wanted to see one of the most energetic presentations at BIO 2015 in Philadelphia you needed to attend the Idea Design Studio Hacking Medicine session put on by MIT. Ned McCague (pictured below) led things off and continued to use his high energy style to keep the attendees not only engaged, but also to help get them actively involved and do some work.
The team of presenters and facilitators posed the idea that anyone can improve the healthcare system because everyone has been a patient. Their view is that by bringing together clinicians, designers, researchers, administrators, and patients for a 48 hour session you can break challenges down to manageable pieces and solve healthcare problems.
June 23, 2015 12:38 PM
Rare disease research advances, antibiotic research continues to slide
Patent filings can be an indicator of what lies ahead for the pharmaceutical industry and by extension, what drugs will be available for healthcare systems around the world. Patent information suggests that drugs for treating rare diseases are getting intense research attention, and development of new antibiotics to treat widespread conditions is still in the midst of a "lost decade". The development of new classes of antibiotics is so low that a new U.K. report says the crisis in antibiotic resistance "has the potential to be catastrophic for human healthcare".
The 2015 Marks & Clerk Life Science Report was released at BIO in Philadelphia last week and it found that less than five per cent of patents filed for antibiotic research since 2004 are for new classes of drugs.